AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2024
Dec 23, 2024
31868_dirs_2024-12-23_6e911378-4b20-4189-81a0-29ef29760518.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2024-12-19
Reporting Person: Doyle Anthony (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-19 | Common Stock | A | 120700 | — | Acquired | 380328 | Direct |
| 2024-12-19 | Common Stock | F | 2461 | $7.39 | Disposed | 377867 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-19 | Emp. Stock Option (Right to Buy) | $7.39 | A | 250100 | Acquired | 2034-12-19 | Common Stock (250100) | Direct |
Footnotes
F1: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.
F3: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.